{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:5487"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:5487","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Factors affecting CD4 T cell recognition of the EBV-encoded tumour antigen EBNA1","abstract":"Epstein-Barr virus (EBV) is associated with 200,000 cases of cancer per year. Although these include B cell lymphomas and epithelial carcinomas, the ability of T cells specific to viral antigens to target the latter, which constitute the majority of cases, has not been explored. In this study I have investigated the processing and CD4 T cell recognition of epithelial cells expressing EBNA1, a virally-encoded protein expressed in all EBV-associated malignancies. EBNA1 was equally stable in B cells and epithelial cells but EBNA1-specific CD4 T cell clones were nevertheless able to recognise both types of target cell. The potential effects of EBV-encoded micro-RNA BART18 on autophagy and CD4 T cell recognition were examined and showed that the loss of BART18 increased the autophagy levels of EBV-positive Jijoye Burkitt lymphoma cells under nutrient starvation conditions. Finally, the effects of a pharmacological inhibitor of EBNA1 dimerisation, JLP2, on the viability and T cell recognition of EBV-positive B cells was also investigated. JLP2 did not increase CD4 T cell recognition but transiently decreased the viability of one of two EBV-positive lymphoblastoid cell lines coincident with this line’s uptake of the drug.","abstract_html":"Epstein-Barr virus (EBV) is associated with 200,000 cases of cancer per year. Although these include B cell lymphomas and epithelial carcinomas, the ability of T cells specific to viral antigens to target the latter, which constitute the majority of cases, has not been explored. In this study I have investigated the processing and CD4 T cell recognition of epithelial cells expressing EBNA1, a virally-encoded protein expressed in all EBV-associated malignancies. EBNA1 was equally stable in B cells and epithelial cells but EBNA1-specific CD4 T cell clones were nevertheless able to recognise both types of target cell. The potential effects of EBV-encoded micro-RNA BART18 on autophagy and CD4 T cell recognition were examined and showed that the loss of BART18 increased the autophagy levels of EBV-positive Jijoye Burkitt lymphoma cells under nutrient starvation conditions. Finally, the effects of a pharmacological inhibitor of EBNA1 dimerisation, JLP2, on the viability and T cell recognition of EBV-positive B cells was also investigated. JLP2 did not increase CD4 T cell recognition but transiently decreased the viability of one of two EBV-positive lymphoblastoid cell lines coincident with this line’s uptake of the drug.","abstract_has_math":false,"creators":["Leonard, Henry"],"institution":"University of Birmingham","degree_name":"m_rs","degree_level":"m_rs","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014-12","date_published":"2014-12","updated_at":"2026-11-19T09:28:23Z","subjects":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/5487/1/Leonard14MRes.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A5487","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Leonard, Henry"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2014-12"]},{"key":"dc:date.issued","label":"Date","values":["2014-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Cancer Studies"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/5487/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["m_rs"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["m_rs"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/5487/1/Leonard14MRes.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Epstein-Barr virus (EBV) is associated with 200,000 cases of cancer per year. Although these include B cell lymphomas and epithelial carcinomas, the ability of T cells specific to viral antigens to target the latter, which constitute the majority of cases, has not been explored. In this study I have investigated the processing and CD4 T cell recognition of epithelial cells expressing EBNA1, a virally-encoded protein expressed in all EBV-associated malignancies. EBNA1 was equally stable in B cells and epithelial cells but EBNA1-specific CD4 T cell clones were nevertheless able to recognise both types of target cell. The potential effects of EBV-encoded micro-RNA BART18 on autophagy and CD4 T cell recognition were examined and showed that the loss of BART18 increased the autophagy levels of EBV-positive Jijoye Burkitt lymphoma cells under nutrient starvation conditions. Finally, the effects of a pharmacological inhibitor of EBNA1 dimerisation, JLP2, on the viability and T cell recognition of EBV-positive B cells was also investigated. JLP2 did not increase CD4 T cell recognition but transiently decreased the viability of one of two EBV-positive lymphoblastoid cell lines coincident with this line’s uptake of the drug."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Factors affecting CD4 T cell recognition of the EBV-encoded tumour antigen EBNA1"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Leonard, Henry"],"dc:date":["2014-12"],"dc:date.issued":["2014-12"],"dc:description.abstract":["Epstein-Barr virus (EBV) is associated with 200,000 cases of cancer per year. Although these include B cell lymphomas and epithelial carcinomas, the ability of T cells specific to viral antigens to target the latter, which constitute the majority of cases, has not been explored. In this study I have investigated the processing and CD4 T cell recognition of epithelial cells expressing EBNA1, a virally-encoded protein expressed in all EBV-associated malignancies. EBNA1 was equally stable in B cells and epithelial cells but EBNA1-specific CD4 T cell clones were nevertheless able to recognise both types of target cell. The potential effects of EBV-encoded micro-RNA BART18 on autophagy and CD4 T cell recognition were examined and showed that the loss of BART18 increased the autophagy levels of EBV-positive Jijoye Burkitt lymphoma cells under nutrient starvation conditions. Finally, the effects of a pharmacological inhibitor of EBNA1 dimerisation, JLP2, on the viability and T cell recognition of EBV-positive B cells was also investigated. JLP2 did not increase CD4 T cell recognition but transiently decreased the viability of one of two EBV-positive lymphoblastoid cell lines coincident with this line’s uptake of the drug."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/5487/1/Leonard14MRes.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Cancer Studies"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/5487/"],"dc:subject":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public"],"dc:title":["Factors affecting CD4 T cell recognition of the EBV-encoded tumour antigen EBNA1"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["m_rs"],"dc:type.qualificationname":["m_rs"]},"updated_at":"2026-11-19T09:28:23Z"}